Optimax Holdings Berhad
Registration No: 201801028697 (1290723-T)
(Incorporated in Malaysia)

**Unaudited Condensed Consolidated Interim Financial Report** for the Fourth Quarter Ended **31 December 2021** 

Optimax Holdings Berhad
Registration No: 201801028697 (1290723-T)
(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of financial position as at 31 December 2021

	Unaudited As at 31 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Assets Property, plant and equipment Right-of-use assets Deferred tax assets	49,266 9,462 369	42,985 9,958 462
Total non-current assets	59,097	53,405
Inventories Trade and other receivables Prepayments Current tax assets Investment in financial assets <sup>(1)</sup> Cash and cash equivalents Total current assets Total assets	3,070 4,563 1,466 433 4,632 19,614 33,778 92,875	2,220 1,454 1,001 112 15,129 10,914 30,830 84,235
<b>Equity</b> Share capital Reserves	39,071 15,967	39,071 8,799
Total equity attributable to owners of the Company Non-controlling interests	55,038 2,704	47,870 2,351
Total equity	57,742	50,221

## Unaudited condensed consolidated statement of financial position as at 31 December 2021 (continued)

	Unaudited As at 30 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Liabilities  Deformed toy liabilities	1.057	1 200
Deferred tax liabilities Loans and borrowings	1,957 12,188	1,280 14,214
Lease liabilities	6,800	7,008
Total non-current liabilities	20,945	22,502
Loans and borrowings	3,620	3,441
Lease liabilities	1,475	1,750
Trade and other payables	8,048	5,785
Current tax liabilities	1,045	536
Total current liabilities	14,188	11,512
Total liabilities	35,133	34,014
Total equity and liabilities	92,875	84,235
Net assets per share attributable to owners of the Company (RM) <sup>(2)</sup>	0.20	0.18

<sup>(1)</sup> Investment in financial assets represents investment in the Affin Hwang Aiiman Money Market Fund with a redemption notice of only one (1) business day.

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Net assets per share attributable to owners of the Company is calculated based on the share capital of 270,000,000 shares after the completion of the restructuring exercise and the Initial Public Offering ("IPO").

#### **Optimax Holdings Berhad**

Registration No: 201801028697 (1290723-T) (Incorporated in Malaysia)

# Unaudited condensed consolidated statement of profit or loss and other comprehensive income for the fourth quarter ended 31 December 2021

	Individual quarter ended 31 December ← Unaudited ← ▶		Cumulativ ended 31 I Unaudited	
	2021	2020	2021	2020
	RM'000	RM'000	RM'000	RM'000
Revenue Other income Inventories and consumables	26,607	17,211	88,898	58,020
	-	66	169	230
	(6,768)	(3,594)	(19,473)	(12,090)
Staff costs Depreciation expenses Other expenses	(9,274)	(6,589)	(34,722)	(22,791)
	(1,516)	(1,537)	(6,580)	(5,955)
	(2,519)	(1,301)	(8,634)	(6,328)
Results from operating activities Finance income Finance costs	6,530	4,256	19,658	11,086
	40	63	191	124
	(235)	(440)	(1,258)	(1,540)
Profit before tax Tax expense Profit and total comprehensive	6,335	3,879	18,591	9,670
	(2,308)	(1,619)	(5,490)	(3,257)
income for the financial period/year	4,027	2,260	13,101	6,413
Profit and total comprehensive income attributable to: Owners of the Company	3,570	2,077	12,298	5,641
	457	183	803	772
Non-controlling interests  Profit and total comprehensive income for the financial period/year	4,027	2,260	13,101	6,413
Earnings per ordinary share (sen)(1)				
- Basic earnings per ordinary share (sen)	1.32	0.91	4.55	2.46
<ul> <li>Diluted earnings per ordinary share (sen)</li> </ul>	1.06	0.70	3.64	1.90

<sup>(1)</sup> Earnings per ordinary share is calculated based on the weighted average number of ordinary shares referred to in Note B10.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Optimax Holdings Berhad
Registration No: 201801028697 (1290723-T)
(Incorporated in Malaysia)

#### Unaudited condensed consolidated statement of changes in equity for the fourth quarter ended 31 December 2021

	← Attributable to owners of the Company — ►  Non-distributable → Distributable						
A codific of	Share capital RM'000	Invested equity <sup>(1)</sup> RM'000	Other reserves RM'000	Retained earnings RM'000	Total RM'000	Non- controlling interests RM'000	Total equity RM'000
Audited At 1 January 2020 <sup>(2)</sup>	*	2,700	(686) <sup>(3)</sup>	20,644	22,658	1,579	24,237
Effect of restructuring <sup>(4)</sup>	19,500	(2,700)	(16,800)	20,044	22,000	1,579	Z <del>4</del> ,201
New shares issued by the Company for	10,000	(2,100)	(10,000)				
the Public Issue <sup>(5)</sup>	21,000	-	-	-	21,000	-	21,000
New shares issuance expenses for							
the Public Issue <sup>(6)</sup>	(1,429)	-	-	-	(1,429)	-	(1,429)
Profit and total comprehensive income for the financial year	_	-	-	5,641	5,641	772	6,413
At 31 December 2020	39,071	_	$(17,486)^{(7)}$	26,285	47,870	2,351	50,221
Unaudited							
At 1 January 2021	39,071	_	$(17,486)^{(7)}$	26,285	47,870	2,351	50,221
Dividends to non-controlling interests	-	-	-	, -	· -	(450)	(450)
Dividends to owners of the Company	-	-	-	(5,130)	(5,130)	-	(5,130)
Profit and total comprehensive income for the financial year		-	-	12,298	12,298	803	13,101
At 31 December 2021	39,071	-	(17,486)	33,453	55,038	2,704	57,742

<sup>\*</sup> Denotes RM1

## Unaudited condensed consolidated statement of changes in equity for the third quarter ended 31 December 2021 (continued)

- <sup>(1)</sup> This represents the Company's investment in Optimax Eye Specialist Centre Sdn. Bhd.
- (2) The comparative figures in the Group's condensed consolidated interim financial report are presented as if the restructuring had occurred before the start of the earliest period presented.
- (3) This represents business combination reserve which arose from the acquisition of two subsidiaries namely Optimax Eye Specialist Centre (Ipoh) Sdn. Bhd. and Optimax Eye Specialist Centre (Seri Petaling) Sdn. Bhd. from a common control shareholder during the financial year ended 31 December 2017.
- (4) The effect of restructuring arose from the restructuring exercise undertaken by the Company in conjunction with the listing of and quotation for the Company's shares on the ACE Market of Bursa Malaysia Securities Berhad ("Bursa Securities").
- (5) Issuance of new shares pursuant to the IPO.
- (6) Listing expenses incurred pursuant to the IPO that has been set-off against equity.
- This consists of business combination reserve of RM686,000 and restructuring reserve of RM16,800,000 as elaborated in (3) and (4) above.

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Optimax Holdings Berhad
Registration No: 201801028697 (1290723-T)
(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of cash flows for the fourth quarter ended 31 December 2021

	Cumul quarter 31 Deco Unaudited	ended
	2021	2020
	RM'000	RM'000
Cash flows from operating activities	40.504	0.070
Profit before tax  Adjustments for:	18,591	9,670
Finance income	(191)	(124)
Finance costs	1,258	1,540
Depreciation of property, plant and equipment	4,880	4,141
Depreciation of right-of-use assets	1,700	1,814
Property, plant and equipment written off	<sup>′</sup> 6	4
Fair value gain on investment in financial assets	(52)	(36)
Gain on derecognition of right-of-use assets	(67)	-
Initial public offering expenses		603
Operating profit before working capital changes Changes in working capital:	26,125	17,612
Inventories	(850)	(410)
Trade and other receivables	(3,109)	900
Prepayments	(465)	136
Trade and other payables	3,000	(1,561)
Cash generated from operations	24,701	16,677
Interest received	47	31
Interest paid	(522)	(631)
Tax refund	- (4.500)	127
Tax paid	(4,532)	(3,248)
Net cash from operating activities	19,694	12,956
Cash flows from investing activities		
Acquisition of property, plant and equipment	(11,084)	(4,558)
Proceeds from disposal of property, plant and equipment	112	( .,555)
Net redemption from/(Increase in) investment in financial assets	10,693	(15,000)
Changes in pledged deposits	(18)	(22)
Net cash used in investing activities	(297)	(19,580)

# Unaudited condensed consolidated statement of cash flows for the fourth quarter ended 31 December 2021 (continued)

	Cumulative quarter ended 31 December	
	Unaudited 2021 RM'000	Audited 2020 RM'000
Cash flows from financing activities	KINI UUU	KIVI UUU
Dividends paid to non-controlling interests	(450)	
Dividends to owners of the Company	(5,130)	-
	(3, 130)	(000)
Interest paid	(736)	(909)
Proceeds from issuance of new shares	-	21,000
Payment of listing expenses	-	(2,037)
Repayment of hire purchase liabilities	(3,319)	(2,110)
Proceeds from hire purchase	1,055	-
Repayment of term loans	(515)	(3,591)
Payment of lease liabilities	(1,620)	(1,560)
Net cash (used in)/from financing activities	_(10,715)	10,793
Net increase in cash and cash equivalents	8,682	4,169
Cash and cash equivalents at the beginning of financial year	9,843	5,674
Cash and cash equivalents at the end of financial year	18,525	9,843

#### (i) Cash and cash equivalents

Cash and cash equivalents included in the consolidated statement of cash flows comprise the following consolidated statement of financial position amounts:

	quarter	2021 2020	
Cash and cash equivalents Pledged deposits	19,614 (1,089) 18,525	10,914 (1,071) 9,843	

O-----

# Unaudited condensed consolidated statement of cash flows for the fourth quarter ended 31 December 2021 (continued)

#### (ii) Acquisition of property, plant and equipment

During the financial year, the Group acquired property, plant and equipment as follows:

	quarter	Cumulative quarter ended 31 December	
	Unaudited 2021 RM'000	Audited 2020 RM'000	
Paid in cash Property, plant and equipment purchased using hire	10,952	3,944	
purchase arrangement	227	3,289(1)	
Balances remained unpaid at financial year end	100	837	
	11,279	8,070	

<sup>(1)</sup> The Group entered into hire purchase arrangement to finance an operation equipment amounting to RM1,950,000 in the financial year ended 31 December 2020 in which deposits of RM975,000 was paid in the financial year ended 31 December 2019.

During the financial year the Group paid the remaining outstanding amounts in relation to property, plant and equipment acquired in the previous financial year of RM132,000 (31.12.2020: RM614,000).

The Group also entered into hire purchase arrangement to fully finance the plant and equipment acquired in the previous financial year of RM1,760,000 (31.12.2020: RM1,168,000) in which RM705,000 (31.12.2020: RM1,668,000) relates to the balances that remained unpaid at the previous financial year end. The remaining RM1,055,000 (31.12.2020: RM Nil) was initially funded out of the Group's internally generated funds in the previous financial year.

## Unaudited condensed consolidated statement of cash flows for the fourth quarter ended 31 December 2021 (continued)

#### (iii) Reconciliation of movements of liabilities to cash flows arising from financing activities

	← At 1.1.2020 RM'000	Audited Acquisition of new Payments lease Remeasurement RM'000 RM'000 RM'000		At Acquisition of new .1.2020 Payments lease Remeasurement		At 31.12.2020 RM'000
Term loans Hire purchase liabilities Lease liabilities	12,423 5,976 8,608	(3,591) (2,110) (1,560)	- 4,957 -	- - 1,710	8,832 8,823 8,758	
	27,007	(7,261)	4,957	1,710	26,413	

	•	Unaudited —				<b></b>
	At		<b>Acquisition of</b>			At
	1.1.2021 RM'000	Payments RM'000	new lease RM'000	Derecognition RM'000	Remeasurement RM'000	31.12.2021 RM'000
Term loans	8,832	(515)	-	-	-	8,317
Hire purchase liabilities(1)	8,823	(3,319)	1,987	-	-	7,491
Lease liabilities	8,758	(1,620)	1,508	(1,103)	732	8,275
	26,413	5,454	3,495	(1,103)	732	24,083

<sup>(1)</sup> The Group entered into hire purchase arrangement to fully finance the plant and equipment acquired in the previous financial year of RM1,760,000 in which RM705,000 relates to the balances that remained unpaid at the previous financial year end. The remaining RM1,055,000 was initially funded out of the Group's internally generated funds in the previous financial year.

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

#### **Optimax Holdings Berhad**

Registration No: 201801028697 (1290723-T)

(Incorporated in Malaysia)

#### PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

#### A1. Basis of preparation

The condensed consolidated interim financial report is unaudited and have been prepared in accordance with the Malaysian Financial Reporting Standards ("MFRS") 134 *Interim Financial Reporting* and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Securities ("Listing Requirements").

Within the context of this condensed consolidated interim financial report for the fourth quarter ended 31 December 2021, the Group comprises Optimax Holdings Berhad ("the Company") and Optimax Eye Specialist Centre Sdn. Bhd. and its subsidiaries ("OESC Group").

The condensed consolidated interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to the condensed consolidated interim financial report. The explanatory notes attached to the condensed consolidated interim financial report provide an explanation of events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2020.

#### A2. Significant accounting policies

Except as described below, the same accounting policies and methods of computation are followed in this condensed consolidated interim financial report as compared with the audited financial statements for the financial year ended 31 December 2020.

As of 1 January 2021, the Group has adopted the following amendments to MFRSs which are effective for annual periods beginning on or after 1 January 2021.

 Amendments to MFRS 9, Financial Instruments, MFRS 139, Financial Instruments: Recognition and Measurement, MFRS 7, Financial Instruments: Disclosures, MFRS 4, Insurance Contracts and MFRS 16, Leases – Interest Rate Benchmark Reform – Phase 2

The Group has early adopted the Amendment to MFRS 16, *Leases - Covid-19-Related Rent Concessions beyond 30 June 2021* issued by MASB in April 2021 in response to the coronavirus disease pandemic.

The adoption of the above pronouncements did not have any material impact to the condensed consolidated interim financial report of the Group.

#### A3. Auditors' report

There was no qualified audit report issued by the auditors in the audited financial statements for the financial year ended 31 December 2020.

#### A4. Seasonal or cyclical factors

The nature of the Group's business was not subject to any significant seasonal and cyclical factors.

#### A5. Exceptional items

There were no material exceptional items during the current financial quarter under review.

#### A6. Material changes in accounting estimates

There were no material changes in accounting estimates for the current financial quarter under review.

## A7. Material events subsequent to the statement of financial position date

Save as disclosed in Note B6 "Status of corporate proposals announced but not completed", there were no material events subsequent to the end of the current financial quarter under review that have not been reflected in the condensed consolidated interim financial report.

#### A8. Material changes in the composition of the Group

There were no material changes in the composition of the Group for the current financial quarter under review.

#### A9. Capital commitments

Outstanding capital commitments in respect of capital expenditure at financial position date not provided for at the end of each reporting period are as follows:

	Unaudited As at 31 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Capital expenditure commitments		
Property, plant and equipment		
Authorised and contracted for	7,160	4,063

#### A10. Debt and equity securities

There were no other issuance, cancellations, repurchases, resale and repayments of debt and equity securities for the current financial quarter under review, except as disclosed in Note B7.

#### A11. Dividends paid

On 24 December 2021, the Company paid a first interim dividend of RM0.019 (2020: Nil) per share in respect of the financial year ended 31 December 2021 amounting to RM5.13 million (2020: Nil).

#### A12. Operating segments

The Group does not have the reportable segments, as the services are managed indistinctly because they require the similar technology and marketing strategies. The internal management reports consist of performance from respective entities and classified as North, Central, South and East Malaysia. The Group's Chief Executive Officer reviews internal management reports at least on a quarterly basis. The following summary describes the geographical segments results:

#### **Geographical segments**

In presenting information on the basis of geographical segments, segment revenue is based on geographical location of customers.

	<b>←</b>	<b>←</b> Unaudited ──→				
	ended 31   2021			ended 31 December ended 31 I 2021 2020 2021		December 2020
	RM'000	RM'000	RM'000	RM'000		
Revenue						
North Malaysia	5,161	3,013	13,734	9,304		
Central Malaysia	15,986	10,067	58,240	35,009		
South Malaysia	4,947	3,751	15,187	11,940		
East Malaysia	513	380	1,737	1,767		
	26,607_	17,211_	88,898	58,020		

#### A13. Valuations of property, plant and equipment

Property, plant and equipment except for freehold land are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Freehold land is stated at cost less accumulated impairment losses, if any.

#### A14. Contingencies

There were no contingent assets and contingent liabilities as at the date of this condensed consolidated interim financial report.

#### A15. Investment in financial assets

The investment in financial assets relates to the funds received pursuant to the IPO. As disclosed in the Prospectus, pending the eventual utilisation of proceeds from the IPO, the funds have been placed in short-term money market instruments.

#### A16. Related party transactions

#### Identity of related parties

For the purposes of this condensed consolidated interim financial report, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control or jointly control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the parties are subject to common control. Related parties may be individuals or other entities.

Related parties also include key management personnel defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly and entity that provides key management personnel services to the Group. The key management personnel include all the Directors and certain members of senior management of the Group.

The Group has related party relationship with a Director and companies in which a Director has financial interest.

#### Significant related party transactions

Significant related party transactions of the Group are as follows:

		<b>←</b> Unaudited —			<b></b>
		Individual quarter ended 31 December		Cumulativ ended 31 I	December
		2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000
Tra	ansactions				
A.	Directors				
	Lease payments	29	66	203	264
	Sales of inventories				(49)
В.	Companies in which Directors have financial interests				
	Lease payments	91	133	439	534
	Purchases of inventories	2	-	2	23
	Service fees payable	25	-	25	-
	Sales of inventories	(309)	(3)	(318)	(19)
	Service fees receivable	(43)		(81)	(23)

#### A17. Fair value information

The carrying amounts of cash and cash equivalents, short-term receivables and payables reasonably approximate their fair values due to the relatively short-term nature of these financial instruments.

The table below analyses other financial instruments at fair value.

	Fair value of financial instruments carried at fair value Level 1 RM'000	Fair value of financial instruments not carried at fair value Level 3 RM'000	Total fair value RM'000	Carrying amount RM'000
Unaudited				
31.12.2021 Financial assets				
Investment in financial				
assets	4,632	-	4,632	4,632
Financial liabilities				
Financial liabilities Term loans	_	(8,925)	(8,925)	(8,317)
Hire purchase liabilities		(7,802)	(7,802)	(7,491)
	_	(16,727)	(16,727)	(15,808)
Audited			, ,	
31.12.2020				
Financial assets Investment in financial				
assets	15,129	-	15,129	15,129
Financial liabilities Term loans		(9,377)	(9,377)	(8 833)
Hire purchase liabilities	-	(9,147)	(9,377) (9,147)	(8,832) (8,823)
•	_	(18,524)	(18,524)	(17,655)

#### A17. Fair value information (continued)

#### Policy on transfer between levels

The fair value of an asset to be transferred between levels is determined as of the date of the event or change in circumstances that caused the transfer.

#### Level 1 fair value

Level 1 fair value is derived from quoted price (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

#### Level 3 fair value

Level 3 fair value is estimated using unobservable inputs for the financial assets and liabilities.

The following table shows the valuation techniques used in the determination of fair values within Level 3, as well as the key unobservable inputs used in the valuation models.

### Type Description of valuation technique and inputs used

Term loans and hire purchase liabilities

Discounted cash flows using a rate based on the current market rate of borrowing of the respective entities at the reporting date.

# PART B - EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF ACE MARKET LISTING REQUIREMENT OF BURSA MALAYSIA SECURITIES BERHAD

#### **B1.** Review of financial performance

(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

#### Current financial quarter against corresponding financial quarter

	Unau Individua ended 31 I		
	2021 RM'000	2020 RM'000	Variance %
Revenue	26,607	17,211	54.59
Profit before tax ("PBT")	6,335	3,879	63.31

The Group reported revenue of RM26.61 million for the current financial quarter under review. This represents an increase in revenue of approximately 54.59% against the corresponding financial quarter of RM17.21 million.

On 15 June 2021, the Government of Malaysia announced the National Recovery Plan ("NRP") which consists of four phases of an exit strategy to help the country emerge from the coronavirus ("COVID-19") pandemic and its economic fallout. The transition from one phase to the next phase will be based on three threshold indicators. The indicators include the average number of daily COVID-19 cases, intensive care unit ("ICU") bed occupancy rate and the national vaccination rates (by having two shots). From 7 August 2021 onwards, the number of new COVID-19 cases with serious symptoms were used to indicate whether a state was ready to move up to Phases 2 and 3 instead and asymptomatic cases were no longer counted. Most of the states had entered into phase 4 in October 2021 (Pahang, Kuala Lumpur, Selangor, Putrajaya, Malacca, Johor and Terengganu) and November 2021 (Sabah, Perlis, Kedah, Penang and Perak).

With the easing and relaxation of certain restrictions under NRP, the Group has seen a gradual recovery in the number of patients, including patients for refractive surgeries and cataract surgeries who postponed their treatments until after the Full Movement Control Order ("FMCO") which came to effect from 1 June 2021 to 28 June 2021.

In the previous financial quarter, the national vaccination programme ("PICK") and MyMedic@Wilayah which are organised by ProtectHealth Corporation Sdn Bhd and Kementerian Wilayah Persekutuan respectively had been rapidly rolled out throughout the country. Through the Group's participation in these two programmes, the Group derived a new revenue stream from the provision of vaccination services. There is still spill over effect from the above 2 programmes as the Group are still involve in administering of booster jabs in the current financial quarter.

#### **B1.** Review of financial performance (continued)

(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued)

## <u>Current financial quarter against corresponding financial quarter</u> (continued)

Besides that, the Group also continued to offer ongoing promotions for its eye specialist services through online platforms as part of its marketing efforts. These have resulted in the increase in revenue during the current financial quarter under review as compared to the corresponding financial quarter.

In terms of geographical segmentation (as tabulated below), the Group recorded an increase in revenue for all geographical segments.

	Individua	Unaudited Individual quarter ended 31 December		
	2021			
Revenue	RM'000	RM'000	%	
North Malaysia	5,161	3,013	71.29	
Central Malaysia	15,986	10,067	58.80	
South Malaysia	4,947	3,751	31.88	
East Malaysia	513	380	35.00	
	26,607	17,211	54.59	

While the Group's revenue for the current financial quarter under review increased by 54.59% as compared to the corresponding financial quarter, the Group's PBT increased by 63.31% from RM3.88 million for the corresponding financial quarter to RM6.34 million for the current financial quarter. The increase in PBT was mainly due to:

- (i) the increase in revenue as elaborated above;
- (ii) effective marketing effort as there are ongoing promotions through online platforms; and
- (iii) better control of operating costs after the Group had encountered multiple lockdowns since March 2020.

#### **B1.** Review of financial performance (continued)

(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued)

#### Current financial year against corresponding financial year

	Cumulativ ended 31 I		
	Unaudited 2021 RM'000	Audited 2020 RM'000	Variance %
Revenue PBT	88,898 18,591	58,020 9,670	53.22 92.25

The Group reported revenue of RM88.90 million for the current financial year, as compared to RM58.02 million in the corresponding financial year, representing an increase of RM30.88 million or 53.22%.

The increase in revenue was mainly due to the easing and relaxation of certain restrictions under the NRP during the current financial year as compared to the previous Movement Control Order ("MCO") and its extension under the Conditional Movement Control Order from 4 May 2020 to 9 June 2020 and Recovery Movement Control Order from 10 June 2020 to 31 December 2020 during the corresponding financial year.

Besides, the Group had participated in PICK and MyMedic@Wilayah as mentioned above. With these two programmes, the Group derived a new revenue stream from the provision of vaccination services, which has contributed positively to the increase of both revenue and PBT.

In terms of geographical segmentation (as tabulated below), save for East Malaysia, the Group recorded increase in revenue for all other geographical segments.

	Cumulative quarter ended 31 December		
	Unaudited 2021 RM'000	Audited 2020 RM'000	Variance %
Revenue			
North Malaysia	13,734	9,304	47.61
Central Malaysia	58,240	35,009	66.36
South Malaysia	15,187	11,940	27.19
East Malaysia	1,737	1,767	(1.70)
	88,898	58,020	53.22

#### **B1.** Review of financial performance (continued)

(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued)

#### <u>Current financial year against corresponding financial year (continued)</u>

While the Group's revenue for the current financial year only increased by 53.22% as compared to the corresponding financial year, the Group's PBT increased by 92.25%. The increase in PBT was mainly due to:

- (i) the increase in revenue as elaborated above;
- (ii) in the corresponding financial year ended 31 December 2020, the Group's revenue had decreased significantly due to the implementation of MCO while a portion of the costs continued to accrued. The major cost items which continue to be accrued including staff costs, depreciation expenses, finance costs and other expenses such as sales and marketing expenses, administration and office expenses, professional fees and insurance;
- (iii) non recurrence of expenses which were incurred in the last corresponding financial year ended 31 December 2020 that were not incurred during the current financial year under review, including:
  - (a) RM0.20 million worth of donation made to the Ministry of Health of Malaysia for the purchase of ventilators, protective gear, test kits and other necessities to combat the COVID-19 outbreak; and
  - (b) RM0.60 million of IPO expenses.

## B2. Variation of results against immediate preceding financial quarter

	Unaเ Individual q		
	31 December 2021 RM'000	30 September 2021 RM'000	Variance %
Revenue PBT	26,607 6,236	29,769 7,198	(10.62) (13.36)

The Group's revenue decreased by 10.62% from RM29.77 million to RM26.61 million

The decrease in revenue was mainly due to the drop in vaccination revenue in the current quarter. The two vaccination programmes peaked from July 2021 to August 2021 where all adults in Malaysia were encouraged to get vaccinated. The primary series of the vaccination involved two doses per adult. However, for the vaccination booster shots which took place from October 2021 onwards, the programmes only involved one dose per adult.

Notwithstanding the above, the Group continued to enjoy an increase in revenue from its eye specialist services in the current financial quarter under review. With the easing and relaxation of certain restriction under NRP, the Group has seen a gradual recovery in the number of patients, including patients coming for refractive surgeries and cataract surgeries which were postponed until after the FMCO from 1 June 2021 to 28 June 2021.

The Group's PBT decreased by RM0.96 million mainly due to the decrease in revenue in the current financial quarter under review.

#### **B3.** Commentary on prospects

On 15 June 2021, the Government of Malaysia announced the introduction of the NRP which consists of four phases of an exit strategy to transition out of the COVID-19 pandemic. The strategy of the NRP is based on three headline indicators: i) average number of daily new cases; ii) utilisation of intensive care unit beds; and iii) percentage of the eligible population fully vaccinated. From 7 August 2021 onwards, the number of new COVID-19 cases with serious symptoms were used to indicate whether a state was ready to move up to Phases 2 and 3 instead and asymptomatic cases were no longer counted. Most of the states had entered into phase 4 in October 2021 (Pahang, Kuala Lumpur, Selangor, Putrajaya, Malacca, Johor and Terengganu) and November 2021 (Sabah, Perlis, Kedah, Penang and Perak).

As a provider of eye specialist services, the Group's business falls within essential services, and thus, the Group was able to continue its operations during the MCO 3.0, FMCO and NRP periods. The Group has also seen a gradual improvement of the performance for some of its branches while some branches' performance were back to the pre-COVID-19 performance since fourth quarter onwards as more states entered into phase 4 of NRP. The Group will continue to monitor the situation to assess and address the impact of the COVID-19 pandemic on its business and financial condition.

#### **B3.** Commentary on prospects (continued)

In addition, with the Group's participation in PICK as mentioned above the vaccination booster shots programmes are expected to continue to contribute positively to the Group's performance.

Accordingly, given the performance of the Group during the financial year ended 31 December 2021, the Group's Directors are of the opinion that the Group's prospects for the financial year ending 31 December 2022 remain favourable.

#### **B4.** Profit forecast

Not applicable as the Group does not publish any profit forecast.

#### **B5.** Tax expense

Tax expense comprises the following:

	<b>←</b>	Unau	dited ———	<b></b>
	Individual quarter ended 31 December		ember ended 31 De	
	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000
Recognised in profit or loss				
Current tax expense Current financial period/year	1,500	1,121	4,720	2,777
Current initiational period/year	1,000	1,121	4,720	2,111
Deferred tax expense				
Current financial period/year	808	498	770	480
=	2,308	1,619	5,490	3,257
Effective tax rate	36.43%	41.74%	29.53%	33.68%

The overall effective tax rates of 36.43% for individual quarter and 29.53% for cumulative quarter ended 31 December 2021 were higher than the statutory tax rate of 24% due to the non-deductible expenses incurred.

Income tax expense in the form of provision is recognised based on management's estimate.

#### B6. Status of corporate proposals announced but not completed

On 30 April 2021, the Group announced the following proposals ("Proposals"):

#### Bonus issue of warrants and employees' share option scheme

(a) Proposed bonus issue of up to 67,500,000 warrants in the Company ("Warrant(s)") on the basis of one (1) Warrant for every four (4) existing ordinary shares in the Company held ("Bonus Issue of Warrants"); and

## B6. Status of corporate proposals announced but not completed (continued)

(b) Proposed establishment of an employees' share option scheme ("ESOS") involving up to 20% of the total number of issued shares of the Company (excluding treasury shares, if any) at any point of time during the duration of the ESOS for eligible executive directors and employees of the Company and its non-dormant subsidiaries.

On 8 November 2021, the circular and notice of the extraordinary general meeting ("EGM") in relation to the Proposals was despatched to the shareholders. All the resolutions tabled in the EGM were approved by the shareholders of the Company on 24 November 2021.

On 2 December 2021, necessary confirmation has been submitted to Bursa Securities and the effective date for the implementation of the ESOS is 2 December 2021.

On 6 January 2022, the Bonus Issue of Warrants has been completed following the listing of and quotation for 67,499,994 Warrants on the ACE Market of Bursa Securities on 6 January 2022.

#### **Proposed Bonus Issue**

On 14 February 2022, the Company announced the proposed bonus issue of up to 404,999,992 ordinary shares in Optimax ("Optimax Share(s)" or "Share(s)") ("Bonus Share(s)") on the basis of 1 Bonus Share for every 1 Optimax Share held on an entitlement date to be determined later ("Proposed Bonus Issue"). The Company is currently preparing the application to seek Bursa Securities' approval for the implementation of the Proposed Bonus Issue.

Save for the above, there are no other corporate proposals announced but not completed for the current financial quarter under review.

#### **B7.** Loans and borrowings

Particulars of the Group's loans and borrowings are as follows:

	Note	Unaudited As at 31 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Non-current Term loans – secured		7,867	8,360
Hire purchase liabilities	B7.1	4,321	5,854
		12,188	14,214
Current		450	470
Term loans – secured Hire purchase liabilities	B7.1	450 3,170	472 2,969
Tille purchase habilities	۱.۱۵		
		3,620	3,441
		15,808	17,655

#### **B7.1** Hire purchase liabilities

Hire purchase liabilities are payable as follows:

	Future minimum lease payments RM'000	Interest RM'000	Present value of minimum lease payments RM'000
Unaudited			
31.12.2021			
Less than one year	3,530	360	3,170
Between one to five years	4,581	260	4,321
	8,111	620	7,491
Audited 31.12.2020			
Less than one year	3,383	414	2,969
Between one to five years	6,254	400	5,854
	9,637	814	8,823

#### **B8.** Material litigation

There are no material litigations as at the date of this report.

#### **B9.** Dividends

On 24 February 2022, the Board of Directors of the Company declared a second interim tax-exempt dividend of 1.90 sen per ordinary share in respect of the financial year ended 31 December 2021. The entitlement date is fixed on 17 March 2022 and payment will be made on 26 March 2022. The total dividends declared to date for the financial year ended 31 December 2021 is 3.80 sen per ordinary share (December 2020: nil).

#### B10. Earnings per ordinary share

The calculation of earnings per ordinary share at 31 December 2021 and 2020, was based on the profit attributable to ordinary shareholders and a weighted average number of ordinary shares outstanding calculated as follows:

	Individual quarter ended 31 December   ✓ Unaudited → 2021 2020		Cumulativ ended 31 I Unaudited 2021	•
Profit for the financial period/year attributable to owners of the Company (RM'000)	3,570	2,077	12,298	5,641
Basic earnings per ordinary share attributable to owners of the Company				
Based on weighted average number of ordinary shares ('000) Earnings per ordinary share (sen)	270,000 1.32	229,167 <sup>(i)</sup> 0.91	270,000 4.55	229,167 <sup>(i)</sup> 2.46
Diluted earnings per ordinary share attributable to owners of the Company				
Based on weighted average number of ordinary shares ('000) Effective of dilution arising from	270,000	229,167 <sup>(i)</sup>	270,000	229,167 <sup>(i)</sup>
conversion of all bonus warrants	67,500	67,500	67,500	67,500
Adjusted weighted average number of ordinary shares ('000)	337,500 <sup>(ii)</sup>	296,667 <sup>(ii)</sup>	337,500 <sup>(ii)</sup>	296,667 <sup>(ii)</sup>
Diluted earnings per ordinary share (sen)	1.06	0.70	3.64	1.90

<sup>(</sup>i) Based on the weighted average number of issued share capital of 200,000,000 ordinary shares after the restructuring but before the IPO and 270,000,000 ordinary shares after the completion of the IPO.

<sup>(</sup>ii) Effect of dilution includes the effect of the bonus issue of warrants which has been completed following the listing and quotation of 67,499,994 warrants on the ACE Market of Bursa Securities on 6 January 2022. As of the date of the report, no warrants have been exercised.

#### **B11.** Trade and other receivables

	Unaudited As at 31 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Current Trade		
Trade receivables	3,432	541
Non-trade		
Other receivables	433	303
Deposits	698	610
	1,131	913
	4,563	1,454
(a) Ageing analysis of trade receivables		
	Unaudited As at 31 December 2021 RM'000	Audited As at 31 December 2020 RM'000
Current (not past due)	1,978	468
1 – 30 days past due	1	30
31 – 120 days past due	1,435	37
More than 120 days past due	18	6
	3,432	541

Trade receivables that are past due have not been impaired as payments have been substantially received from these debtors subsequent to year end.

### **B12. Profit before tax**

		Individua end 31 Dec	led	Cumulative quarter ended 31 December Unaudited Audited		
	Note	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	
Material expenses/ (income)						
Depreciation expenses - property, plant and						
equipment		1,118 469	1,084 453	4,880	4,141	
<ul> <li>right-of-use assets</li> <li>Initial public offering</li> </ul>		409	433	1,700	1,814	
expenses Property, plant and		-	-	-	603	
equipment written off		-	4	6	4	
Fair value gain on investment in financial						
assets		(9)	(36)	(52)	(36)	
Finance income - investment in financial						
assets		(26)	(56)	(144)	(93)	
<ul> <li>cash and cash equivalents</li> </ul>		(14)	(7)	(47)	(31)	
Finance costs		,	( )	, ,		
<ul><li>bank overdraft</li><li>term loans</li></ul>		- 72	- 110	2 253	30 431	
<ul><li>term loans</li><li>hire purchase liabilities</li></ul>		118	187	483	478	
- lease liabilities		56	143	520	601	
Donation		-	8	520	208	
COVID-19 related rent			J		200	
concession					(76)	

#### **B12.** Profit before tax (continued)

		Individua end 31 Dec <b>←</b> Unau	ded	Cumulative quarter ended 31 December Unaudited Audited	
	Note	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000
Expenses arising from leases					
Expenses relating to short-term leases	(i)	163	1	539	122
Expenses relating to leases of low-value					
assets	(ii)	32	4	146	15
Gain on derecognition of right-of-use assets		(1)		(67)	

- (i) The Group leases operation equipment with contract terms of less than 1 year. These leases are short-term in nature and the Group has elected not to recognise right-of-use assets and lease liabilities for these leases.
- (ii) The Group leases various office equipment with contract terms of 3 years. These leases are low-value in nature and the Group has elected not to recognise right-of-use assets and lease liabilities for these leases.

The Group did not report any other income including investment income, provision for and write off of receivables, provision for and write off of inventories, gain or loss on disposal of quoted or unquoted investments or properties, impairment of assets, foreign exchange gain or loss and gain or loss on derivatives.

#### **B13. Utilisation of proceeds**

The status on the utilisation of proceeds from the IPO of RM21.00 million is as follows:

Purpose	Intended timeframe for utilisation upon listing	Proposed utilisation		Amount utilised as at the date of this report		Deviation	
		RM'000	%	RM'000	%	RM'000	%
Capital expenditure	Within 24 months	10,354	49.31	8,078	78.02	$(2,276)^{(1)}$	(21.98)
Repayment of borrowings	Within 3 months	3,520	16.76	3,520	100.00	-	-
Working capital	Within 12 months	3,526	16.79	3,526	100.00	-	-
Estimated listing expenses	Within 1 month	3,600	17.14	3,600	100.00	-	-
Total		21,000	100.00	18,724	89.16	(2,276)	(10.84)

The utilisation of the proceeds as disclosed above should be read in conjunction with the Prospectus.

<sup>(1)</sup> The allocated IPO proceeds for capital expenditure has not been fully utilised as at the date of this report. The Group has announced that the timeframe for the utilisation of proceeds allocated for capital expenditure will be extended for another 12 months. Accordingly, the timeframe for the utilisation of proceeds allocated for capital expenditure will be for a period of up to 24 months from 18 August 2020, being the date of the listing of and quotation for the Company's entire enlarged issued capital on the ACE Market of Bursa Malaysia Securities Berhad.